Utah Medical Products, Inc. (UTMD) Income Statement

The sequential pattern shows revenue stabilizing in a narrow $8.5M to $8.7M band across the last three quarters, which suggests the decline is flattening rather than accelerating. However, the year-over-year comparisons remain negative, indicating the base has not yet turned, and investors should monitor whether this plateau represents a true trough or a temporary pause. The absence of any quarter showing positive growth warrants caution about the durability of the franchise's demand base.

The margin expansion appears to reflect a combination of cost reduction in cost of goods sold and possible mix or pricing effects, though the filings alone do not isolate which driver dominated. Gross margin subsequently moderated to 55.6% and 56.1% in the two most recent quarters, suggesting the 2026Q1 peak may not be sustained. Relative to the peer set, where LMAT reports 71.5% and NVCR 74.5%, UTMD's margin profile remains mid-range, which may limit evidence of structural pricing power.

Operating income has moved in rough proportion to revenue, which suggests that operating expenses have been adjusted to track the top line rather than producing meaningful operating leverage in either direction. The SG&A line shows considerable quarterly volatility, including a figure of $7.6M in 2024Q4 that appears anomalous relative to adjacent quarters and warrants further investigation before drawing efficiency conclusions. The data does not clearly demonstrate that operating income is scaling faster than gross profit, so the efficiency case remains unproven on this evidence.